Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Healthy Tadulako Journal (Jurnal Kesehatan Tadulako)
Ramadhani, Muhammad Zulmi
Unknown Affiliation
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
PD-1 and PDL-1 Immune Checkpoint Inhibitors: Emerging Hope for the Future of Lung Cancer Immunotherapy Ilyasa, Muhammad Riza; Ramadhani, Muhammad Zulmi; Santoso, Rex Jeremy; Hutasoit, Gina Andyka; Miskad, Upik Anderiani
Healthy Tadulako Journal (Jurnal Kesehatan Tadulako) Vol. 11 No. 3 (2025)
Publisher : Faculty of Medicine, Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22487/htj.v11i3.1723

Abstract

Background: Lung cancer is the leading cause of cancer-related deaths worldwide, with Non-Small Cell Lung Cancer (NSCLC) being the most common type. Despite advances in treatment, the prognosis remains poor. Immune checkpoint inhibitors targeting PD-1 and PD-L1 have emerged as a promising first-line treatment approach in combating cancer. Objectives: This literature review aims to evaluate the effectiveness of PD-1 and PD-L1 immune checkpoint inhibitors in the treatment of NSCLC. It also explores the potential of these inhibitors to improve patient survival rates compared to conventional therapies. Methods: A systematic literature search was conducted using databases such as PubMed, Google Scholar, ScienceDirect, and NCBI, with keywords including "PD-1," "PD-L1," "NSCLC," "lung cancer," and "immunotherapy." Results: All four inhibitors significantly improve survival rates compared to traditional chemotherapy. Atezolizumab and pembrolizumab show high effectiveness in patients with high PD-L1 expression. Durvalumab, when combined with chemotherapy, overcomes resistance mechanisms. Nivolumab, enhancing survival rates. Conclusion: PD-1 and PD-L1 inhibitors provide substantial benefits in the treatment of NSCLC, including increased survival rates and reduced need for aggressive therapies. Further research should focus on optimizing combination therapies to expand the therapeutic benefits of these inhibitors.
Co-Authors Gina Andyka Hutasoit Ilyasa, Muhammad Riza Santoso, Rex Jeremy UPIK ANDERIANI MISKAD, UPIK ANDERIANI